ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients

American Journal of Cancer Research

Volumn 3, Issue 2, 2013, Pages 221-229

  Ricci, Francesca ^a   Bernasconi, Sergio ^a   Porcu, Luca ^a   Erba, Eugenio ^a   Panini, Nicolò ^a   Fruscio, Robert ^b   Sina, Federica ^b   Torri, Valter ^a   Broggini, Massimo ^a   Damia, Giovanna ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

ALDH activity; CD133; Ovarian carcinoma

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL RENEWAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 84894253553     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB,Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD and Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011; 11: 719-725.
2. Rasheed ZA, Kowalski J, Smith BD and Matsui W. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells 2011; 29: 883-887.
3. Alison MR, Lim SM, and Nicholson LJ. Cancer stem cells: problems for therapy?. J Pathol 2011; 223: 147-161.
4. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, and Dirks PB. Tumour-initiating cells: challenges, and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806-823.
5. Tysnes BB. Tumor-initiating, and -propagating cells: cells that we would like to identify, and control. Neoplasia 2010; 12: 506-515.
6. Curley MD, Garrett LA, Schorge JO, Foster R, and Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011; 16: 368-392.
7. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, and Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27: 2875-2883.
8. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, and Murphy SK. Epigenetic regulation of CD133, and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28: 209-218.
9. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC Jr, Coleman RL, Lopez-Berestein G, and Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010; 9: 3186-3199.
10. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Butzow R, Coukos G, and Zhang L. Distinct expression levels, and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010; 5: e10277.
11. Burgos-Ojeda D, Rueda BR, and Buckanovich RJ. Ovarian cancer stem cell markers: prognostic, and therapeutic implications. Cancer Lett 2012; 322: 1-7.
12. Yoshida A, Rzhetsky A, Hsu LC, and Chang C. Human aldehyde dehydrogenase gene family. Eur J Biochem 1998; 251: 549-557.
13. Marcato P, Dean CA, Giacomantonio CA, and Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011; 10: 1378- 1384.
14. Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, and Nolta JA. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104: 1648-1655.
15. Corti S, Locatelli F, Papadimitriou D, Donadoni C, Salani S, Del Bo R, Strazzer S, Bresolin N, and Comi GP. Identification of a primitive brainderived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006; 24: 975-985.
16. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky SH, Birnbaum D, Viens P, and Wicha MS. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis, and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45- 55.
17. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, and Boman BM. Aldehyde dehydrogenase 1 is a marker for normal, and malignant human colonic stem cells (SC), and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009; 69: 3382-3389.
18. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, and Zou W. Expression of aldehyde dehydrogenase, and CD133 defines ovarian cancer stem cells. Int J Cancer 2012; 130: 29-39.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, and Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
20. Ricci F, Bernasconi S, Perego P, Ganzinelli M, Russo G, Bono F, Mangioni C, Fruscio R, Signorelli M, Broggini M, and Damia G. Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle 2012; 11: 1966-1976.
21. Saw YT, Yang J, Ng SK, Liu S, Singh S, Singh M, Welch WR, Tsuda H, Fong WP, Thompson D, Vasiliou V, Berkowitz RS, and Ng SW. Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues, and sphere cultures. BMC Cancer 2012; 12: 329.
22. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, and Lai HC. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance,, and poor clinical outcome. Am J Pathol 2012; 180: 1159-1169.
23. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, and Liu J. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009; 22: 817-823.
24. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, and Luborsky JL. Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary, and serous ovarian tumors. J Ovarian Res 2010; 3: 28.
25. Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, and Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) 2012; 5: 484-491.
26. Balicki D. Moving forward in human mammary stem cell biology, and breast cancer prognostication using ALDH1. Cell Stem Cell 2007; 1: 485-487.
27. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, and Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009; 178: 48-55.
28. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, Giacomantonio CA, and Lee PW. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3, and its expression is predictive of metastasis. Stem Cells 2011; 29: 32-45.
29. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, and Scambia G. Expression of CD133-1, and CD133-2 in ovarian cancer. Int J Gynecol Cancer 2008; 18: 506-514.
30. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, and Scambia G. CD133 antigen expression in ovarian cancer. BMC Cancer 2009; 9: 221.
31. Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, and Liu J. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 2012; 25: 456-464.
32. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS, and Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001.